WA
PTGX icon

Whipplewood Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Whipplewood Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7K Hold
22
– – ﹤0.01% 381
2026
Q1 		$2.32K Buy
+22
New +$1.95K ﹤0.01% 747
2025
Q3 		– Sell
-22
Closed -$1.22K – 951
2025
Q2 		$1.22K Buy
+22
New +$1.06K ﹤0.01% 982

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Whipplewood Advisors's PTGX Position: Q2 2026 in Review

Whipplewood Advisors held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 22 shares worth $2.7K. The position accounts for ﹤0.01% of the portfolio, ranked #381.

Whipplewood Advisors first reported a position in PTGX in Q2 2025 and has held it in 3 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Whipplewood Advisors held 22 shares of Protagonist Therapeutics worth $2.7K as of Q2 2026.
  • Whipplewood Advisors left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Whipplewood Advisors's portfolio in Q2 2026, its #381 holding.
  • Whipplewood Advisors first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Whipplewood Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.